Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.37
(3.02%)
SEK 1.37
(3.02%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -923 Thousand SEK | 84.23% |
| 2022 | -5.85 Million SEK | 32.18% |
| 2021 | -8.62 Million SEK | -803.83% |
| 2020 | 1.22 Million SEK | -49.48% |
| 2019 | 2.42 Million SEK | 138.43% |
| 2018 | -6.31 Million SEK | -56.73% |
| 2017 | -4.02 Million SEK | 62.65% |
| 2016 | -10.78 Million SEK | -318.99% |
| 2015 | -2.57 Million SEK | -20995.95% |
| 2014 | -12.2 Thousand SEK | 72.52% |
| 2013 | -44.4 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.85 Million SEK | -12.33% |
| 2024 Q1 | -1.65 Million SEK | -79.31% |
| 2023 Q2 | -4.11 Million SEK | -1.78% |
| 2023 FY | -923 Thousand SEK | 84.23% |
| 2023 Q4 | -923 Thousand SEK | 20.43% |
| 2023 Q1 | -4.04 Million SEK | 30.95% |
| 2023 Q3 | -1.16 Million SEK | 71.8% |
| 2022 Q1 | -3.68 Million SEK | 57.28% |
| 2022 FY | -5.85 Million SEK | 32.18% |
| 2022 Q3 | -1.58 Million SEK | -306.27% |
| 2022 Q4 | -5.85 Million SEK | -270.38% |
| 2022 Q2 | 766 Thousand SEK | 120.78% |
| 2021 Q3 | -14.91 Million SEK | -342.31% |
| 2021 FY | -8.62 Million SEK | -803.83% |
| 2021 Q2 | -3.37 Million SEK | 40.2% |
| 2021 Q4 | -8.62 Million SEK | 42.16% |
| 2021 Q1 | -5.64 Million SEK | -560.03% |
| 2020 Q3 | -1.44 Million SEK | 68.84% |
| 2020 Q1 | 7.35 Million SEK | 203.13% |
| 2020 FY | 1.22 Million SEK | -49.48% |
| 2020 Q2 | -4.65 Million SEK | -163.21% |
| 2020 Q4 | 1.22 Million SEK | 184.61% |
| 2019 Q4 | 2.42 Million SEK | 262.45% |
| 2019 FY | 2.42 Million SEK | 138.43% |
| 2019 Q3 | -1.49 Million SEK | 71.58% |
| 2019 Q2 | -5.25 Million SEK | 23.49% |
| 2019 Q1 | -6.87 Million SEK | -8.8% |
| 2018 FY | -6.31 Million SEK | -56.73% |
| 2018 Q2 | -13.4 Million SEK | -1292.88% |
| 2018 Q1 | -962.53 Thousand SEK | 0.0% |
| 2018 Q3 | -9.66 Million SEK | 27.89% |
| 2018 Q4 | -6.31 Million SEK | 34.68% |
| 2017 Q2 | -10.78 Million SEK | 21.18% |
| 2017 FY | -4.02 Million SEK | 62.65% |
| 2017 Q1 | -13.68 Million SEK | 23.04% |
| 2017 Q3 | -7.67 Million SEK | 28.86% |
| 2016 Q4 | -17.78 Million SEK | 0.0% |
| 2016 FY | -10.78 Million SEK | -318.99% |
| 2016 Q2 | -2.57 Million SEK | 0.0% |
| 2015 FY | -2.57 Million SEK | -20995.95% |
| 2015 Q3 | 12.2 Thousand SEK | 0.0% |
| 2014 FY | -12.2 Thousand SEK | 72.52% |
| 2013 FY | -44.4 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | 95.652% |
| Amniotics AB (publ) | -5.63 Million SEK | 83.612% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | 57.288% |
| BioArctic AB (publ) | -606.58 Million SEK | 99.848% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 117.093% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.921% |
| Cantargia AB (publ) | -139.74 Million SEK | 99.34% |
| Genovis AB (publ.) | -43.94 Million SEK | 97.899% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 98.898% |
| Mendus AB (publ) | -96.29 Million SEK | 99.041% |
| Kancera AB (publ) | -45.69 Million SEK | 97.98% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 98.877% |
| LIDDS AB (publ) | -13.51 Million SEK | 93.169% |
| Lipum AB (publ) | -8.46 Million SEK | 89.096% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 97.109% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 101.734% |
| NextCell Pharma AB | -46.79 Million SEK | 98.027% |
| OncoZenge AB (publ) | -12.62 Million SEK | 92.69% |
| Saniona AB (publ) | 40.44 Million SEK | 102.282% |
| Simris Alg AB (publ) | 85.07 Million SEK | 101.085% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 99.723% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 100.556% |
| Xintela AB (publ) | -7.8 Million SEK | 88.18% |
| Ziccum AB (publ) | -2.13 Million SEK | 56.809% |
| AcouSort AB (publ) | -23.98 Million SEK | 96.152% |
| Active Biotech AB (publ) | -33.2 Million SEK | 97.22% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 96.859% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 95.157% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 99.332% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 99.287% |
| CombiGene AB (publ) | -101.44 Million SEK | 99.09% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 98.876% |
| Intervacc AB (publ) | -88.16 Million SEK | 98.953% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 98.155% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 98.152% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 104.5% |
| Corline Biomedical AB | -17.01 Million SEK | 94.574% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 98.898% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 97.656% |
| Aptahem AB (publ) | 2.9 Million SEK | 131.733% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 99.72% |
| Fluicell AB (publ) | -2.76 Million SEK | 66.594% |
| Biovica International AB (publ) | -58.73 Million SEK | 98.429% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 97.959% |
| Abliva AB (publ) | -57.24 Million SEK | 98.387% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 99.526% |
| 2cureX AB (publ) | -13.4 Million SEK | 93.113% |
| I-Tech AB | -83.26 Million SEK | 98.891% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 100.685% |
| Cyxone AB (publ) | -16.67 Million SEK | 94.463% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 98.348% |
| Biosergen AB | -1.88 Million SEK | 50.982% |
| Nanologica AB (publ) | -9.38 Million SEK | 90.168% |
| SynAct Pharma AB | -61.75 Million SEK | 98.505% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 95.69% |
| BioInvent International AB (publ) | -236.3 Million SEK | 99.609% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 93.023% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 98.621% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 82.185% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 95.561% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 68.943% |